Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b clinical trial of CPI818 for the treatment of relapsed/refractory T-cell lymphomas (TCL)

Next Previous
X
Search
Trial Profile

A Phase 1/1b clinical trial of CPI818 for the treatment of relapsed/refractory T-cell lymphomas (TCL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soquelitinib (Primary)
  • Indications Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 06 May 2024 Updated interim data as of May 3, 2024 (n=25) from this trial, published in a Corvus Pharmaceuticals media release.
    • 07 Nov 2023 According to a Corvus Pharmaceuticals media release, new interim data from this study will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
    • 15 Jun 2023 According to a Corvus Pharmaceuticals media release, as of May 2023,30 patients were enrolled in the optimum 200 mg dose, including 20 evaluable for tumor response.A total of ten patients remained on therapy, including six who have not had their initial tumor response evaluation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top